BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Pamungkas KMN, Lesmana Dewi PIS, Alamsyah AZ, Dewi NLPY, Dewi NNGK, Mariadi IK, Sindhughosa DA. Microbiome dysbiosis and immune checkpoint inhibitors: Dual targets in Hepatocellular carcinoma management. World J Hepatol 2025; 17(7): 106810 [PMID: 40747222 DOI: 10.4254/wjh.v17.i7.106810]
URL: https://www.wjgnet.com/2222-0682/full/v17/i7/106810.htm
Number Citing Articles
1
Vivek Kumar, Amit Chaudhary, Mansi Gautam, Pankaj Verma, Meenu Singh. Microbiome and cancer: mechanistic insights, diagnostic potential, and therapeutic strategiesFrontiers in Cell and Developmental Biology 2026; 14 doi: 10.3389/fcell.2026.1844436
2
Robert Kucharski, Adam Kosiński, Leszek Kalinowski, Karolina Kaźmierczak-Siedlecka. Ipilimumab, -omics, and head and neck cancers—update in 2025Frontiers in Immunology 2026; 17 doi: 10.3389/fimmu.2026.1737862
3
Meiqi Zhang, Yao Lu, Xingxing Yuan. The tumor microenvironment: a dynamic ecosystem and therapeutic nexus in modern oncologyFrontiers in Pharmacology 2026; 17 doi: 10.3389/fphar.2026.1836055
4
Laura Sneller, Keshav Mathur, Shyam Kottilil, Poonam Mathur. Hot and Cold HCC: Uncoupling Viral Oncogenesis and TherapyViruses 2025; 17(9) doi: 10.3390/v17091255
5
Ghaleb Oriquat, Amr Ali Mohamed Abdelgawwad El-Sehrawy, Waleed K. Abdulsahib, Wael Waleed Mustafa, S. Renuka Jyothi, Priya Priyadarshini Nayak, J. Bethanney Janney, Gurjant Singh, Aashna Sinha, Farzaneh Yazdi. Probiotic, synbiotic effects on the gut–liver axis: omics-enabled mechanisms and therapeutic windowsFuture Microbiology 2026; 21(8) doi: 10.1080/17460913.2026.2684877